27 March 2023

Hierarchy of Banks’ Liabilities

The Credit Suisse Write-Down of AT1 instruments has taken market participants by surprise, but it seems to be the result of the exercise of discretionary powers by the Swiss regulator rather than the establishment of a new market standard.

Given the current regulatory framework under Luxembourg and EU law, it seems unlikely that AT1 instruments issued by Luxembourg based institutions are written down before CET1 instruments had al-ready absorbed all the losses they could. Investors should take a closer look beforehand at the contractual terms of the AT1 instruments they intend to subscribe.

The GSK Update provides further insights regarding additional tier 1 instruments’ principal write down under Luxembourg and EU legislation.

Print


Press contact
Beate Dünschede
+352 271802-29
beate.duenschede@gsk-lux.com

Back

GSK Updates
  • 11.09.2023

    GSK Update: Application of the law on a national screening mechanism for foreign direct investments in Luxembourg

    Read more
  • 17.07.2023

    GSK Update: Bill of Law: Modernising the Luxembourg Investment Funds Toolbox

    Read more
  • 06.04.2023

    GSK Update: Bill of Law: Modernising the Luxembourg Investment Funds Toolbox

    Read more
Contact person

Andreas Heinzmann, LL.M. eur.

Partner

+352 271802-30

andreas.heinzmann@gsk-lux.com

Dr. Manuel Fernandez

Local Partner

+352 271802-31

manuel.fernandez@gsk-lux.com

Valerio Scollo, LL.M. (NYU), LL.M. (NUS)

Local Partner

+352 271802-32

valerio.scollo@gsk-lux.com

Christoforos Naziroglou

Associate

+352 271802-362

christoforos.naziroglou@gsk-lux.com

© GSK Stockmann 2023